LiraglutideCheck methods and identity
What the ELAD trial measured in the brains of people with Alzheimer’s disease
3 numbered sourcesSource years 2025
Peptides are short chains of amino acids linked by peptide bonds. Some can change cell activity by activating a receptor. Liraglutide is a peptide that activates the GLP-1 receptor and is approved for specific uses in diabetes and weight management, depending on the product. The ELAD trial studied it in people with mild to moderate Alzheimer’s disease, an investigated use. The researchers focused on whether they could detect a change in how the brain used glucose. [1, 2, 3]
The phase 2b trial randomized 204 adults without diabetes to liraglutide or placebo for 52 weeks. It used a type of PET scan that tracks a glucose-like tracer to estimate glucose metabolism in the brain. The study also included assessments of memory, executive function and ability to carry out everyday activities. Those measures help distinguish an imaging result from changes a participant or caregiver might observe. [1]
The investigators did not find a statistically significant difference in the primary measure of brain glucose metabolism. They reported a difference favoring liraglutide on a secondary executive function measure, with an unadjusted statistical test. They did not find significant differences on the reported everyday activities or overall dementia rating measures. The pattern is more informative when read outcome by outcome than if the paper is reduced to whether one test favored the drug. [1]
A phase 2 study can help determine which measures to carry into a larger study. When multiple secondary measures are considered, an individual result can be more uncertain than the main comparison. The secondary cognitive finding gives researchers a specific result to investigate again. The primary imaging test and the other measures provide context for how much was established in this trial. [1]
ELAD’s findings apply to a defined group of adults with mild to moderate disease and a one-year follow-up. They do not expand the FDA-approved indications. The trial is an example of researchers testing a plausible pathway in people and finding that the main measured response was uncertain despite an interesting result on one secondary measure. [1, 2, 3]
Sources
Original works cited in this article. Links open the external record in a new tab.
